Aquestive Therapeutics, Inc. (AQST) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• Aquestive Therapeutics (AQST) Q1 2026: 66% Revenue Jump Driven by Royalty Windfall and Debt Refi Runway
  May 14, 2026
• AQST Q4 2025: 50% Salesforce Expansion Signals Aggressive Anafilm Launch Readiness
  March 05, 2026
• Aquestive Therapeutics (AQST) Q3 2025: $160M Capital Secured to Fund Anafilm Launch and Pipeline Acceleration
  November 06, 2025
• Aquestive Therapeutics (AQST) Q2 2025: Pre-Launch Spend Rises $4.2M as Anafilm Nears FDA Decision
  August 12, 2025
• Aquestive Therapeutics (AQST) Q1 2025: $8.7M Revenue Drop Highlights Anafilm Launch Bet
  July 06, 2025
• AQST Q3 2024: R&D Spend Up 66% as Anafilm and AQST-108 Pipeline Advance
  November 05, 2024
• Aquestive Therapeutics (AQST) Q2 2024: Revenue Up 52% on Deferred Recognition, Anafilm Nears NDA Milestone
  August 07, 2024
• AQST Q1 2024: $77.5M Raise Extends Runway, Accelerates Anafilm and Libervant Commercial Prep
  May 08, 2024
• Aquestive Therapeutics (AQST) Q4 2023: Royalty Revenue Jumps 104% as Oral Rescue Pipeline Nears Pivotal Milestones
  March 06, 2024

Browse all companies